BJ Jones
About BJ Jones
William “BJ” Jones is Chief Commercial Officer at NewAmsterdam Pharma (NAMS), joining in August 2023; he leads commercial and medical affairs across marketing, market access, sales, medical science engagement, and enterprise operations (age 61) . Jones previously built Biohaven’s commercial capability and launched Nurtec ODT prior to Biohaven’s acquisition by Pfizer (Oct 2022), and led sales/commercial operations at Takeda’s general medicine unit; he serves on the boards of Apogee Therapeutics (APGE) and Annexon Biosciences (ANNX), and holds degrees from the U.S. Air Force Academy (B.S.), Texas A&M (M.S.), and Stanford GSB (MBA) . Company performance context: NewAmsterdam’s TSR rose to 235.78 in 2024 from 102.48 in 2023 while net income was -$242M in 2024 vs -$177M in 2023 .
| Performance Metric | FY 2023 | FY 2024 |
|---|---|---|
| TSR (Value of $100 invested) | 102.48 | 235.78 |
| Net Income ($USD Millions) | (177) | (242) |
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| NewAmsterdam Pharma Company N.V. | Chief Commercial Officer | Aug 2023–present | Leads commercialization and medical affairs; builds launch readiness across multiple markets . |
| Biohaven Pharmaceuticals Holding Co. Ltd. | Chief Commercial Officer, Migraine & Common Diseases | Apr 2019–Dec 2022 | Built commercial capability and launched Nurtec ODT; Biohaven acquired by Pfizer Oct 2022 . |
| Takeda Pharmaceutical Company Ltd. | VP, Head of Sales & Commercial Operations (General Medicine) | Jan 2016–Mar 2019 | Led U.S. sales and commercial operations for general medicine . |
External Roles
| Organization | Role | Years |
|---|---|---|
| Apogee Therapeutics, Inc. (Nasdaq: APGE) | Director | Current (as of Apr 15, 2025) |
| Annexon Biosciences, Inc. (Nasdaq: ANNX) | Director | Current (as of Apr 15, 2025) |
Fixed Compensation
- BJ Jones’ specific base salary, target bonus %, and actual bonus payouts are not disclosed in the proxy (he is not a 2024/2025 NEO). Company policy for executives comprises base salary, annual performance-based cash bonuses, and long-term equity awards .
Performance Compensation
Company annual bonus design and 2024 corporate goals (which drive executive payouts) are below.
| Metric | Weighting | Target Definition | Actual 2024 Achievements | Notes/Payout Impact |
|---|---|---|---|---|
| Clinical Development | 40% (stretch +75%) | Advance Phase 3 programs and key milestones | Met PREVAIL enrollment (~9,500 randomized), initiated REMBRANDT; positive Phase 3 BROOKLYN, TANDEM, BROADWAY topline results . | Corporate performance exceeded 2024 goals (board determined) . |
| CMC (Supply & Launch Readiness) | 5% | On-time clinical supply and launch readiness | Not individually quantified; incorporated in overall determination . | Corporate performance exceeded goals . |
| Finance | 20% | Adequate funding and runway | Feb 2024 offering: net $190.0M; Dec 2024 offering: net $453.4M . | Positive achievement supporting above-target payouts . |
| IP/Operations/BD | 15% (stretch +25%) | Patents/trademarks; key hires; BD activities | USPTO issued patent No. 12,006,305 (composition of matter; Orange Book listing) protecting obicetrapib until July 2043 . | Positive achievement supporting above-target payouts . |
| Commercial/Medical Affairs | 20% | Develop and execute launch plan in multiple markets | Goal in plan; achievement reflected within overall performance outcome . | Corporate performance exceeded goals . |
| Overall Corporate Performance Outcome | — | — | Board determined corporate performance “exceeded 2024 goals” . | NEO payouts spanned 150%–200% of target depending on individual performance . |
Equity Ownership & Alignment
- Beneficial ownership: BJ Jones’ individual holdings are not itemized in the 2025 beneficial ownership table; executive officers and directors as a group own 25,076,239 shares (20.84% of outstanding) .
- Hedging/pledging: Company policy prohibits officers/directors from hedging or pledging company securities .
- Clawback: Incentive Compensation Recoupment Policy compliant with SEC/Nasdaq for restatements .
- Option structure: Executive options carry a 10-year term, strike at grant-date closing price, and time-vest 25% at one year then in equal monthly installments over 36 months .
Employment Terms
- BJ Jones’ specific employment agreement, severance, and change-of-control terms are not disclosed.
- Company practice for NEOs: 12 months’ base salary severance, pro-rated current-year bonus, and COBRA premium reimbursement upon termination without cause/for good reason; double-trigger equity acceleration in change-of-control scenarios .
Investment Implications
- Launch execution leverage: As CCO, Jones’ remit aligns directly with the Commercial/Medical Affairs bonus metric (20% weight), indicating incentives tied to launch readiness for obicetrapib across target markets .
- Retention profile: Company-standard four-year vesting on options (25%/1-year then monthly) creates ongoing retention incentives; anti-hedging/anti-pledging and clawback policies support alignment and risk control .
- Disclosure gaps: Absence of BJ-specific salary, bonus targets, and equity grant detail limits precision on pay-for-performance calibration; monitor future proxies and Form 4 filings for grant/exercise activity and any selling pressure indicators .
- Broader context: Strong 2024 financing ($190.0M and $453.4M net proceeds) and patent extension to 2043 strengthen commercialization runway; corporate performance exceeded 2024 goals, with NEO payouts above target, suggesting aligned execution momentum into launch .